Abstract
Objectives
The ideal assessment after mifepristone and misoprostol for undesired pregnancy of
unknown location (PUL) is unknown.
Study design
We prospectively followed patients at Planned Parenthood League of Massachusetts (2019–2021)
with PUL who received immediate mifepristone and misoprostol with serial at-home urine
pregnancy tests (UPT) and in-office serum HCGs.
Results
Of 13 patients, 10 had a successful medication abortion. For those who completed UPTs
(N = 9), all were negative by Day 14. Two abnormal pregnancies had positive UPTs on
Day 14.
Conclusion
A negative UPT on Day 14 may help determine complete abortion after medication abortion
for undesired PUL. A positive UPT on Day 14 warrants further evaluation.
Implication
Patients taking mifepristone and misoprostol in the setting of undesired PUL who cannot
access serum testing may consider an at-home UPT to confirm complete abortion.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Medication abortion now accounts for more than half of all US abortions.Guttmacher Institute [Internet]. 2022; ([accessed October 7, 2022]. Available from:)
- Abortion surveillance - United States, 2019.MMWR Surveill Summ. 2021; 70: 1-29https://doi.org/10.15585/mmwr.ss7009a1
- Mifepristone and misoprostol for undesired pregnancy of unknown location.Obstet Gynecol. 2022; 139: 771-780https://doi.org/10.1097/AOG.0000000000004756
- Mifepristone and misoprostol for early abortion when no gestational sac is present.Contraception. 2001; 63: 251-254https://doi.org/10.1016/s0010-7824(01)00200-1
- Termination of pregnancy at very early gestation without visible yolk sac on ultrasound.J Fam Plann Reprod Health Care. 2015; 41: 90-95https://doi.org/10.1136/jfprhc-2014-100924
- Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.Contraception. 2013; 87: 855-858https://doi.org/10.1016/j.contraception.2012.10.013
- Efficacy and safety of very early medical termination of pregnancy: a cohort study.Bjog. 2017; 124: 1993-1999https://doi.org/10.1111/1471-0528.14904
- Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial.Reprod Sci. 2017; 24: 731-737https://doi.org/10.1177/1933719116669055
- Pregnancy of unknown location: a consensus statement of nomenclature, definitions, and outcome.Fertil Steril. 2011; 95: 857-866https://doi.org/10.1016/j.fertnstert.2010.09.006
- Ectopic pregnancy.N Engl J Med. 2009; 361: 379-387https://doi.org/10.1056/NEJMcp0810384
- Verifying the effectiveness of medical abortion; ultrasound versus HCG testing.Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195https://doi.org/10.1016/s0301-2115(03)00012-5
Article info
Publication history
Published online: January 09, 2023
Accepted:
December 16,
2022
Received in revised form:
December 8,
2022
Received:
October 20,
2022
Edited By: Carolyn WesthoffFootnotes
Conflicts of interest: The authors have no conflicts of interest. The findings and conclusions expressed in this article are those of the authors and do not necessarily reflect the views of Planned Parenthood Federation of America, Inc. or the Society of Family Planning Research Fund.
Funding: This work was supported by the Society of Family Planning Research Fund [SFPRF19-11].
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
